These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20085009)

  • 21. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
    Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
    J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer.
    Trenti E; Pycha S; Mian C; Schwienbacher C; Hanspeter E; Kafka M; Spedicato GA; Vjaters E; Degener S; Pycha A; D'Elia C
    Cancer Cytopathol; 2020 May; 128(5):341-347. PubMed ID: 31977131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of urothelial bladder cancer cells in voided urine can be improved by a combination of cytology and standardized microsatellite analysis.
    Wild PJ; Fuchs T; Stoehr R; Zimmermann D; Frigerio S; Padberg B; Steiner I; Zwarthoff EC; Burger M; Denzinger S; Hofstaedter F; Kristiansen G; Hermanns T; Seifert HH; Provenzano M; Sulser T; Roth V; Buhmann JM; Moch H; Hartmann A
    Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1798-806. PubMed ID: 19454613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-invasive diagnostic tests for bladder cancer: a review of the literature.
    Bassi P; De Marco V; De Lisa A; Mancini M; Pinto F; Bertoloni R; Longo F
    Urol Int; 2005; 75(3):193-200. PubMed ID: 16215303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
    Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
    JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant methylation of RARbeta2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer.
    Eissa S; Swellam M; El-Khouly IM; Kassim SK; Shehata H; Mansour A; Esmat M; Nossier AI; Hamdy MA; Awad NM; El-Ahmady O
    Cancer Epidemiol Biomarkers Prev; 2011 Aug; 20(8):1657-64. PubMed ID: 21680534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
    Zuiverloon TC; Beukers W; van der Keur KA; Munoz JR; Bangma CH; Lingsma HF; Eijkemans MJ; Schouten JP; Zwarthoff EC
    BJU Int; 2012 Mar; 109(6):941-8. PubMed ID: 21756281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
    Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
    Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
    Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
    Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.
    Urakami S; Shiina H; Enokida H; Kawakami T; Kawamoto K; Hirata H; Tanaka Y; Kikuno N; Nakagawa M; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2109-16. PubMed ID: 16609023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
    Parekattil SJ; Fisher HA; Kogan BA
    J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC).
    Roperch JP; Hennion C
    BMC Med Genet; 2020 May; 21(1):112. PubMed ID: 32448160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
    Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
    Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
    Kehinde EO; Al-Mulla F; Kapila K; Anim JT
    Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The diagnostic value of microsatellite LOH analysis and the prognostic relevance of angiogenic gene expression in urinary bladder cancer].
    Szarvas T
    Magy Onkol; 2009 Dec; 53(4):385-9. PubMed ID: 20071311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer.
    Moonen PM; Merkx GF; Peelen P; Karthaus HF; Smeets DF; Witjes JA
    Eur Urol; 2007 May; 51(5):1275-80; discussion 1280. PubMed ID: 17084511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection.
    Park HS; Park WS; Bondaruk J; Tanaka N; Katayama H; Lee S; Spiess PE; Steinberg JR; Wang Z; Katz RL; Dinney C; Elias KJ; Lotan Y; Naeem RC; Baggerly K; Sen S; Grossman HB; Czerniak B
    J Natl Cancer Inst; 2008 Oct; 100(19):1401-11. PubMed ID: 18812553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
    Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
    Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.